Fresolimumab ( DrugBank: Fresolimumab )
3 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 51 | Scleroderma | 1 |
| 222 | Primary nephrotic syndrome | 4 |
| 274 | Osteogenesis Imperfecta | 1 |
51. Scleroderma
Clinical trials : 523 / Drugs : 608 - (DrugBank : 156) / Drug target genes : 114 - Drug target pathways : 215
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01284322 (ClinicalTrials.gov) | January 2011 | 25/1/2011 | Fresolimumab In Systemic Sclerosis | OPEN LABEL TRIAL OF ANTI-TGF-BETA MAB, FRESOLIMUMAB, IN SYSTEMIC SCLEROSIS - A PHASE ONE BIOMARKER TRIAL | Diffuse Systemic Sclerosis | Drug: Fresolimumab | Boston University | NULL | Completed | 18 Years | N/A | Both | 18 | Phase 1 | United States |
222. Primary nephrotic syndrome
Clinical trials : 285 / Drugs : 285 - (DrugBank : 108) / Drug target genes : 62 - Drug target pathways : 191
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2012-002365-35-DE (EUCTR) | 15/07/2013 | 11/03/2013 | A Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis (FSGS) | A Phase 2, Multicenter, Double-Blind, Parallel Dosing, Randomized Study of Fresolimumab or Placebo in Patients with Steroid-Resistant Primary Focal Segmental Glomerulosclerosis | Focal segmental glomerulosclerosis MedDRA version: 14.1;Level: PT;Classification code 10067757;Term: Focal segmental glomerulosclerosis;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Not possible to specify | Product Name: Fresolimumab Product Code: GC1008 INN or Proposed INN: Fresolimumab Other descriptive name: GZ402669 | Genzyme Corporation | NULL | Not Recruiting | Female: yes Male: yes | 125 | Phase 2 | France;United States;Brazil;Spain;Germany;Italy | ||
| 2 | EUCTR2012-002365-35-IT (EUCTR) | 22/05/2013 | 20/03/2013 | A Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis (FSGS) | A Phase 2, Multicenter, Double-Blind, Parallel Dosing, Randomized Study of Fresolimumab or Placebo in Patients with Steroid-Resistant Primary Focal Segmental Glomerulosclerosis | Focal segmental glomerulosclerosis MedDRA version: 15.1;Level: PT;Classification code 10067757;Term: Focal segmental glomerulosclerosis;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Not possible to specify | Product Name: Fresolimumab Product Code: GC1008 INN or Proposed INN: Fresolimumab Other descriptive name: GZ402669 | Genzyme Corporation | NULL | Not Recruiting | Female: yes Male: yes | 125 | Phase 2 | France;United States;Brazil;Spain;Germany;Italy | ||
| 3 | EUCTR2012-002365-35-ES (EUCTR) | 19/04/2013 | 09/04/2013 | A Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis (FSGS) | A Phase 2, Multicenter, Double-Blind, Parallel Dosing, Randomized Study of Fresolimumab or Placebo in Patients with Steroid-Resistant Primary Focal Segmental Glomerulosclerosis | Focal segmental glomerulosclerosis MedDRA version: 14.1;Level: PT;Classification code 10067757;Term: Focal segmental glomerulosclerosis;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Not possible to specify | Product Name: Fresolimumab Product Code: GC1008 INN or Proposed INN: Fresolimumab Other descriptive name: GZ402669 | Genzyme Corporation | NULL | Not Recruiting | Female: yes Male: yes | 125 | Phase 2 | France;United States;Brazil;Spain;Germany;Italy | ||
| 4 | NCT01665391 (ClinicalTrials.gov) | August 2012 | 13/8/2012 | A Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis (FSGS) | A Phase 2, Multicenter, Double-Blind, Parallel Dosing, Randomized Study of Fresolimumab or Placebo in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis | Primary Focal Segmental Glomerulosclerosis | Drug: fresolimumab;Drug: Placebo | Genzyme, a Sanofi Company | NULL | Completed | 18 Years | N/A | Both | 36 | Phase 2 | United States;Brazil;Germany;Italy;Spain |
274. Osteogenesis Imperfecta
Clinical trials : 87 / Drugs : 103 - (DrugBank : 20) / Drug target genes : 14 - Drug target pathways : 76
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03064074 (ClinicalTrials.gov) | November 15, 2017 | 13/10/2016 | Safety of Fresolimumab in the Treatment of Osteogenesis Imperfecta | Multicenter Study to Evaluate Safety of Fresolimumab in Adults With Moderate-to-severe Osteogenesis Imperfecta | Osteogenesis Imperfecta | Drug: Fresolimumab | Baylor College of Medicine | Genzyme, a Sanofi Company;Oregon Health and Science University | Recruiting | 18 Years | N/A | All | 16 | Phase 1 | United States |